Johnson & Johnson
NYSE:JNJ
Intrinsic Value
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. [ Read More ]
The intrinsic value of one
JNJ
stock under the Base Case scenario is
139.51
USD.
Compared to the current market price of 155.75 USD,
Johnson & Johnson
is
Overvalued by 10%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Johnson & Johnson's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Johnson & Johnson
| Current Assets | 60.6B |
| Cash & Short-Term Investments | 28.5B |
| Receivables | 16.8B |
| Other Current Assets | 15.3B |
| Non-Current Assets | 131B |
| Long-Term Investments | 493m |
| PP&E | 20.6B |
| Intangibles | 91.7B |
| Other Non-Current Assets | 18.4B |
| Current Liabilities | 54.2B |
| Accounts Payable | 10.4B |
| Accrued Liabilities | 29.3B |
| Short-Term Debt | 9.8B |
| Other Current Liabilities | 4.6B |
| Non-Current Liabilities | 62.4B |
| Long-Term Debt | 33.9B |
| Other Non-Current Liabilities | 28.5B |
JNJ Profitability Score
Profitability Due Diligence
Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Johnson & Johnson's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
JNJ Solvency Score
Solvency Due Diligence
Johnson & Johnson's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Johnson & Johnson's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JNJ Price Targets Summary
Johnson & Johnson
According to Wall Street analysts, the average 1-year price target for
JNJ
is 187.29 USD
with a low forecast of 168.67 USD and a high forecast of 225.75 USD.
Ownership
JNJ Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
JNJ Price
Johnson & Johnson
| Average Annual Return | 8.01% |
| Standard Deviation of Annual Returns | 11.08% |
| Max Drawdown | -27% |
| Market Capitalization | 405B USD |
| Shares Outstanding | 2 598 730 000 |
| Percentage of Shares Shorted | 1.37% |
JNJ News
Last Video News
Johnson & Johnson
Last Important Events
Johnson & Johnson
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Johnson & Johnson
Company Profile
Johnson & Johnson
Country
Industry
Market Cap
Dividend Yield
Description
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
Contact
IPO
Employees
Officers
The intrinsic value of one
JNJ
stock under the Base Case scenario is
139.51
USD.
Compared to the current market price of 155.75 USD,
Johnson & Johnson
is
Overvalued by 10%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
